Arrowhead Research Corp (NASDAQ:ARWR) Investor Investigation Concerning Potential Securities Laws Violations Announced

If you purchased shares of Arrowhead Research Corp (NASDAQ:ARWR), you have certain options and you should contact the Shareholders Foundation, Inc.

To have your information reviewed for options and to recieve notifications about this investigation, please use this form. You may also send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Company Name(s): 
Arrowhead Research
Affected Securities: 
NASDAQ: ARWR

October 10, 2014 (Shareholders Foundation) - An investigation on behalf of investors of Arrowhead Research Corp (NASDAQ:ARWR) shares over potential securities laws violations by Arrowhead Research and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Arrowhead Research Corp (NASDAQ:ARWR) concerning whether a series of statements by Arrowhead Research regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. Arrowhead’s pipeline includes clinical programs in chronic hepatitis B virus and partner-based programs in obesity and oncology. ARC-520 is an RNAi-based therapeutic designed to treat chronic hepatitis B virus (HBV) infection. Shares of Arrowhead Research Corp (NASDAQ:ARWR) grew from $9.79 per share in May 2014 to as high as $16.96 per share in September 2014.

On October 8, 2014, Arrowhead Research Corp announced that data from the ongoing Phase 2a study of ARC-520, its RNAi therapeutic candidate for the treatment of chronic hepatitis B (HBV) infection, will be presented in the late-breaking poster session at the 2014 American Association for the Study of Liver Diseases (AASLD) Liver Meeting being held on November 7-11, 2014, in Boston.
On that same day, an article was published on that claimed Arrowhead Research CEO Chris Anzalone and his team knew for months that ARC-520 dosed at 1 mg/kg and 2 mg/kg yielded 0.2-log and 0.3-log reductions in hepatitis B viral load.

On October 9, 2014, Arrowhead Research Corp issued an open letter to shareholders from President and CEO of Arrowhead Research Corp.

Shares of Arrowhead Research Corp (NASDAQ:ARWR) declined from $13.01 per share on October 7, 2014, to as low as $5.47 per share on October 8, 2014, respectively $6.75 per share on October 9, 2014.